Search clinical trials for: Tolvaptan

Total 116 results

Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, Belgium, Germany, Poland, Spain, United Kingdom
Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA) (DOVA)

Nephropathy

Denmark
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
NYU Langone Health

Withdrawn

Fractional Urate Excretion in Nonedematous Hyponatremia

SIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic Osmostat

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Polycystic Kidney, Autosomal Dominant

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Inappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte Imbalances

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Pilot Study of Using Copeptin to Predict Response to Tolvaptan

Heart Diseases | Cardiovascular Diseases | Heart Failure

United States
Otsuka Beijing Research Institute

Completed

Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

Ascites | Hepatic Cirrhosis

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Germany, United Kingdom, Spain, Sweden, Hungary, Czech Republic, Denmark
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH

Antidiuretic Hormone, Inappropriate Secretion

Japan
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders (TROUPER)

Congestive Heart Failure

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Edema, Cardiac

Japan
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
University of Chicago

Completed

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients (TOLVAD)

Heart Failure | Heart Assist Device | Hyponatremic

United States
Brigham and Women's Hospital
Otsuka Pharmaceutical Co., Ltd.

Completed

The Role of Vasopressin Antagonism on Renal Sodium Handling

Healthy
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Gia Dinh People Hospital
Otsuka Pharmaceutical Vietnam

Recruiting

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF)

Acute Heart Failure

Vietnam
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

Heart Failure, Congestive

United States, Romania
Assistance Publique - Hôpitaux de Paris
Otsuka Pharmaceutical Europe Ltd

Unknown

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) (TOLVATHIRST)

Healthy Volunteers

France
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)

Edema | Heart Failure, Congestive

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Congestive Heart Failure

Japan
Cardiovascular Clinical Science Foundation

Completed

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management (Secret of CHF)

Heart Failure

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

Healthy

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Congestive Heart Failure

Japan
Vanderbilt University

Completed

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

Heart Failure

United States
The Christ Hospital

Completed

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure (TUF)

Acute Decompensated Heart Failure

United States
Emory University

Completed

AiDing Diuresis wIth Tolvaptan (ADD-IT) (ADD-IT)

Congestive Heart Failure | Cardiomyopathy

United States
Shanghai Chest Hospital

Completed

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Right Heart Failure | Tricuspid Regurgitation

China
Oakland University
Georgetown University

Completed

V2 Receptor Effects on Fluid Regulation and Performance

Hyponatremia | Hypernatremia | Electrolyte Imbalance

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Congestive Heart Failure

United States, Canada, Netherlands, United Kingdom, France, Spain, Germany, Switzerland, Italy, Brazil, Argentina, Russian Federation, Belgium, Romania, Czech Republic, Norway, Poland, Sweden
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT-2 Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Hyponatremia | Inappropriate ADH Syndrome | Water Intoxication | Water-electrolyte Imbalance

Germany
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

Congestive Heart Failure

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

Congestive Heart Failure

Canada, United States
Lisbet Brandi

Unknown

Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease (PoCKET)

Autosomal Dominant Polycystic Kidney

Denmark
Hunter Holmes Mcguire Veteran Affairs Medical Center
Otsuka America Pharmaceutical

Completed

Effect of Tolvaptan on Cognitive Function in Cirrhosis

Hepatic Encephalopathy | Cirrhosis | Hyponatremia

United States
King's College Hospital NHS Trust

Recruiting

Low-dose Tolvaptan for Inpatient Hyponatraemia.

Hyponatremia | SIADH

United Kingdom
Regional Hospital Holstebro

Completed

Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD (POLY)

Polycystic Kidney, Autosomal Dominant

Denmark
University of North Carolina, Chapel Hill
Medical University of South Carolina; Otsuka America Pharmaceutical; Barnes-Jewish...

Terminated

Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients

Brain Injury | Hyponatremia

United States
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact

Healthy

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Recruiting

Samsca PMS in ADPKD Patients

Safety

Korea, Republic of
Otsuka Frankfurt Research Institute GmbH

Unknown

Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice

SIADH | Non-SIADH Hyponatremia | Non-Hyponatremia

Denmark, Germany, Italy, Norway, Spain, Sweden, United Kingdom

Search clinical trials for: Tolvaptan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations